Top Markets
Coin of the day
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Rang in Aktien #17486
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Aktienkurs
$0.8034
Marktkapitalisierung
$236.69M
Veränderung (1 Tag)
-8.69%
Veränderung (1 Jahr)
-22.00%
Land
US
Handel Invivyd, Inc. (IVVD)

Kategorie

Dividendenrendite-Verlauf für Invivyd, Inc. (IVVD)
Dividendenrendite (TTM) von Invivyd, Inc. (Aktienkürzel: IVVD) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Invivyd, Inc. (IVVD) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
2.48%
AU
0.00%
CH